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Abstract: Developing nontraditional approaches to the synthesis and characterization of multivalent
compounds is critical to our efforts to study and interface with biological systems and to build new
noncovalent materials. This paper demonstrates a biomimetic approach to the construction of discrete,
modular, multivalent receptors via molecular self-assembly in aqueous solution. Scaffolds presenting
1–3 viologen groups recruit a respective 1-3 copies of the synthetic host, cucurbit[8]uril, in an
noncooperative manner and with a consistent equilibrium association constant (Ka) value of 2 x 106 M-1
per binding site. The assembled mono-, di-, and trivalent receptors bind to their cognate target peptides
containing 1-3 Trp residues with Ka values in the range 1.7 x 104 to 4.7 x 106 M-1 and in predetermined
mono- or multivalent binding modes with 31-280-fold enhancements in affinity and additive enthalpies
due to multivalency. The extent of valency was determined directly by measuring the visible chargetransfer absorptivity due to the viologen-indole pair. The predictable behavior of this system and its
ease of synthesis and analysis make it well suited to serve as a model for multivalent binding and for the
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multivalent recognition of peptides by design.

Introduction
The simultaneous association of multiple ligands on one entity with multiple receptors on another—
“multivalent binding”—is believed to play a fundamental role in myriad biochemical processes,
including signal transduction, pathogenic infection and the immune response, and is involved in the
bottom-up molecular self-assembly of nanoscale architectures.1 Exploring new methods for the
synthesis and characterization of multivalent compounds is therefore critical to our efforts to study and
interface with biological systems and to build new materials. In recent years, substantial interest in this
field has produced a wide range of synthetic multivalent compounds1a,
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as well as experimental

methods and theoretical models to describe their behavior.3 Despite the successful development of many
compounds that exhibit increased affinity and/or selectivity due to multivalency, however, little is
known about how to control the cooperation of multiple binding events by design.

Figure 1. Structures of Q8, MV, and Trp, and a schematic of the Q8•MV•Trp complex.

Progress in this area has been slowed by difficulties inherent to synthesizing multivalent receptors
and to determining the number of simultaneous interactions per complex. The principle approach to
synthesizing multivalent compounds involves covalently connecting multiple copies of a ligand,2b or a
synthetic host (e.g., cyclodextrin, vancomycin, or crown ether),4 either by direct linkage or by
attachment to a common scaffold. While this approach is typically straightforward for the linkage of
small ligands, the linkage of large, polar, and structurally repetitive host compounds is exceedingly slow
and costly, especially for iterative structure-activity studies. Moreover, standard equilibrium binding
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assays are based on comparing the relative quantities of bound and unbound states but do not readily
reveal the extent of valency (i.e., the number of simultaneous associations) in the bound state.5 This
paper describes a multivalent system, based on cucurbit[8]uril (Q8, Figure 1), that overcomes these
issues of synthesis and analysis.
Q8 is a member of the cucurbit[n]uril (Qn) family of synthetic macrocyclic hosts, 6 which have
gained enormous interest in recent years due to their ability to bind tightly and selectively to a wide
range of cationic organic compounds in aqueous solution.7 The methylene-bridged glycoluril units of a
Qn molecule surround its hydrophobic cavity and present ureido carbonyl oxygens at the two
constricted entrances (or portals) to this cavity. These structural features promote binding through a
combination of hydrophobic inclusion of the guest and alignment of its cationic group(s) with the
oxygen atoms of the Qn. While Q5, Q6, and Q7 typically bind one equivalent of organic guest, multiple
guests can be accommodated simultaneously by Q8,6b, 8 Q10,9 and nor-seco-Q10.10 Q8 binds to one
equivalent of methyl viologen (MV) with an equilibrium association constant (Ka) value of 105-106 M–
1 8a, 11

,

and the resulting Q8•MV complex can then bind efficiently to electron-rich aromatic guests such

as dopamine or tryptophan (Trp).12 We have previously reported the binding of Q8•MV to Trpcontaining peptides with Ka values in the range 103-105 M-1, depending on the peptide sequence.11
Moreover, the binding of Trp to Q8•MV is accompanied by the quantitative formation of a new visible
absorbance (hence, optical sensing) due to a charge-transfer complex between the indole and viologen
groups.11,

12b

The interesting properties of the Q8•MV•Trp system led us to consider a biomimetic

approach to making model multivalent receptors.
Living systems use hierarchical organization to efficiently accomplish a broad diversity of function.
At each level of hierarchy, the components carry out functions intrinsic to that level and also have the
ability to work together to achieve higher-level functions. For example, proteins such as cell-surface
receptors or viral capsid proteins can bind their targets in a monovalent fashion and also have the ability
to assemble noncovalently into multivalent structures with increased affinity and/or selectivity of
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binding, or with new function such as pore formation or encapsulation.1a, d Here we show how Q8 can
mimic these proteins via its unique ability to bind selectively to two different guests: 1) a target peptide;
and 2) a viologen that can be used to direct its noncovalent assembly with other Q8 molecules. In the
scheme shown in Figure 2, two molecules of Q8 assemble onto a scaffold presenting two viologen
groups. The resulting self-assembled receptor then binds in a discrete divalent fashion to a peptide with
two tryptophan residues.

Figure 2. Schematic illustration of the concept of a self-assembling modular receptor. A divalent scaffold presenting viologen groups (in red)
recruits two equivalents of Q8, and the resulting receptor binds in a divalent fashion to a peptide with two tryptophan groups (in blue).

Peptide-based scaffolds functionalized with one, two, or three (n) viologen groups were prepared by
solid phase methods.

Isothermal titration calorimetry was used to determine the thermodynamic

parameters for the binding of these compounds to n equivalents of Q8 (i.e., receptor assembly), and for
the binding of the resulting self-assembled receptors to peptides containing n Trp residues, respectively.
We find that all receptors assemble in a noncooperative manner and then bind to their cognate peptide
targets in predetermined mono- or multivalent modes with 31- to 280-fold increases in affinity due to
multivalency, all in aqueous solution at pH 7. The built-in optical sensor, based on the Trp-MV chargetransfer complex, allows for direct quantitation of the extent of valency in each complex using UVvisible spectroscopy. To the best of our knowledge, this is the first time it has been possible to direct
the noncovalent assembly of multiple synthetic hosts into discrete multivalent constructs while still
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maintaining the capacity for the hosts to bind to a target guest. Moreover, the predictable behavior of
this system and its ease of synthesis and analysis make it well suited to serve as a model for multivalent
binding and for the multivalent recognition of peptides by designed molecules.13

Results
Synthesis.

Compounds 1-6 (Figure 3)14 were synthesized on solid-support by standard fmoc

protocols, purified by reversed phase HPLC, and characterized by 1H NMR, analytical HPLC, and mass
spectrometry. For compounds 1-3 we developed a new synthetic strategy for linking viologen groups to
a peptide on solid support.

Briefly, dimethylbenzyl-protected glutamic acid (Glu) residues were

installed at positions where viologen groups were to be coupled. After acetylation of the N-terminal
amine, the Glu residues were deprotected in dilute acid, then activated with pentafluorophenol and
diisopropylcarbodiimide and coupled in situ to an aminoethyl derivative of methyl viologen (see
Supporting Information for details).
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Figure 3. Chemical structures of compounds 1-6.

Equilibrium Binding Studies. The binding of Q8 to compounds 1-3 was measured by ITC to
determine the stoichiometry and affinity of complexation.15 The data in Table 1 show that scaffold
compounds 1, 2, and 3 bind to one, two, and three molar equivalents of Q8 to form receptor complexes
1•Q8, 2•Q82, and 3•Q83, respectively. Ka values were virtually identical for all scaffolds tested. The
presence of all complexes was confirmed by electrospray mass spectrometry (ESI-MS).

Table 1. Binding of Scaffolds to Q8.
Scaffold

Ka (M-1)a

6

1a

2.1 (±0.1) x 106

1b

2.0 (±0.1) x 106

2a

2.2 (±0.3) x 106

2b

2.1 (±0.2) x 106

3

1.6 (±0.1) x 106

a

Data were fit to a one set of sites model in Origin 7.0 software. Standard deviations are given in
parentheses. Values were determined from at least three ITC experiments in 10 mM sodium phosphate,
pH 7.0, at 27 C.

Receptors were preassembled by mixing viologen-containing compounds, 1, 2, and 3, with one, two,
and three molar equivalents of Q8, respectively. Binding of the resulting receptor complexes, 1•Q8,
2•Q82, and 3•Q83, to target peptides 4-6 was measured by ITC to determine the stoichiometry and
thermodynamic parameters of complexation (Table 2). The divalent and trivalent receptor complexes
were kept in the sample cell of the calorimeter at concentrations at or above 20 µM to ensure that the
majority of Q8 was bound to viologen during the experiment. Monovalent, divalent, and trivalent
receptors, 1•Q8, 2•Q82, and 3•Q83, bound to one, two, and three molar equivalents, respectively, of
monovalent target peptides, 4 (i.e., 4a and 4b). Each divalent receptor, 2•Q82, bound to one equivalent
of divalent peptides, 5, and the trivalent receptor, 3•Q83, bound to one equivalent of trivalent peptide,
6.16 The presence of all complexes was confirmed by ESI-MS.
Average Ka values were consistently 2 x 104 M-1 for complexation with monovalent peptides, 4.
The increase in binding affinity due to multivalency was an average 31-fold for divalent complexes,
2•Q82•5, and 280-fold for the trivalent complex, 3•Q83•6. In all cases, binding was exothermic (∆H <
0), enthalpically driven (|∆H| > |T∆S|), and entropically unfavorable (–T∆S > 0). The magnitude of
enthalpy and entropy increased with the valency of the target peptide.

Divalent complexes had

approximately twice the enthalpy of the monovalent complexes (average ∆∆H = -11.7 kcal/mol), but
more than twice the entropy (average -T∆∆S = 9.7 kcal/mol), resulting in the 31-fold increase in
affinity.

The trivalent complex had approximately three times the enthalpy of the monovalent
7

complexes (∆∆H = -26.9 kcal/mol), but substantially more than three times the entropy (-T∆∆S = 23.5
kcal/mol), resulting in the 280-fold increase in affinity.

Table 2. Thermodynamic Data for Binding of Assembled Receptors to Target Peptides.

Receptor Target

n

a

Kab

Gc

Hb

-TSd

(M-1)

(kcal/mol)

(kcal/mol)

(kcal/mol)

1a•Q8

4a

1.02

2.2 (±0.1) x 104

-5.9 (±0.1)

-10.8 (±0.1)

4.9 (±0.1)

1a•Q8

4b

1.06

2.2 (±0.1) x 104

-6.0 (±0.1)

-11.0 (±0.1)

5.0 (±0.1)

1b•Q8

4a

1.03

1.9 (±0.1) x 104

-5.9 (±0.1)

-10.8 (±0.2)

4.9 (±0.2)

1b•Q8

4b

1.03

2.2 (±0.1) x 104

-6.0 (±0.1)

-11.0 (±0.1)

4.9 (±0.1)

2a•Q82

4a

2.07

1.7 (±0.1) x 104

-5.8 (±0.1)

-12.8 (±0.2)

7.0 (±0.2)

2a•Q82

4b

2.07

1.5 (±0.1) x 104

-5.8 (±0.1)

-13.0 (±0.3)

7.2 (±0.4)

2b•Q82

4a

1.95

1.8 (±0.2) x 104

-5.8 (±0.1)

-11.8 (±0.1)

5.9 (±0.1)

2b•Q82

4b

1.94

1.4 (±0.1) x 104

-5.7 (±0.1)

-12.3 (±0.1)

6.6 (±0.1)

2a•Q82

5a

1.05

5.0 (±0.1) x 105

-7.8 (±0.1)

-24.2 (±0.1)

16.3 (±0.1)

2a•Q82

5b

1.07

4.6 (±0.1) x 105

-7.8 (±0.1)

-24.8 (±0.4)

17.1 (±0.4)

2b•Q82

5a

1.04

5.5 (±0.1) x 105

-7.9 (±0.1)

-23.4 (±0.1)

15.6 (±0.1)

2b•Q82

5b

1.01

5.0 (±0.1) x 105

-7.8 (±0.1)

-24.3 (±0.2)

16.5 (±0.2)

3•Q83

4a

2.97

1.7 (±0.1) x 104

-5.8 (±0.1)

-12.2 (±0.1)

6.4 (±0.2)

3•Q83
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1.01

4.7 (±0.8) x 106 e

-9.2 (±0.1) e

-39.4 (±1.4) e

30.2 (±1.5) e

a

Observed molar ratio of target:receptor. Standard deviations are less than 4%. b Mean values
measured from at least three ITC experiments at 27 C in 10 mM sodium phosphate, pH 7.0. Standard
deviations are given in parentheses. c Gibbs free energy values calculated from Ka values. Standard
deviations for G values were calculated as the relative error observed in Ka, due to their relationship by
a natural logarithm. d Entropic contributions to G calculated from Ka and H values, with error
propagated from that of Ka and H. e Data for the 3•Q83•6 complex were determined as described in
footnote 16.

UV-Visible Spectroscopy.

Figure 4 shows an overlay of UV-visible spectra for complexes

1a•Q8•4a, 2a•Q82•5a, and 3•Q83•6, plotted as molar absorptivities.17 The average charge-transfer
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absorptivity at 480 nm (480) for all 2•Q82•5 complexes (795 ± 9 M-1cm-1) was twice that for all 1•Q8•4
complexes (391 ± 8 M-1cm-1), and the 480 for 3•Q83•6 (1193 M-1cm-1) was three times the average 480
for all 1•Q8•4 complexes.

Figure 4. UV-visible spectra of representative monovalent (1a•Q8•4a), divalent (2a•Q82•5a), and trivalent complexes (3•Q83•6), plotted in
molar absorptivity.

Discussion
Design Considerations. Compounds 1-6 (Figure 3) have the principle advantage of being easy to
synthesize and modify. In designing this series, we addressed several important issues: 1) The linkage
between binding sites can participate in binding and must therefore be controlled if one wants to obtain
a meaningful comparison between monovalent and higher valency complexes. We addressed this issue
by designing the compounds in a truly modular fashion, where divalent and trivalent compounds are
two-fold and three-fold repeats of their monovalent analogues, including the peptide backbone. 2) To
help ensure that multiple binding sites on a single compound can interact simultaneously with their
targets, we designed the linkage between binding sites to be conformationally flexible and of sufficient
length to accommodate multiple Q8 molecules. A logical starting point was to make the Trp-containing
9

target peptides, 4-6,14 sequentially analogous to the viologen-containing scaffold compounds, 1-3, using
flexible Gly residues for the linkage. We found that an exact trivalent analogue of 4a has a solubility
limit of ~1 M, which precludes analysis by ITC (while keeping viologen•Q8 complexes saturated). An
analogue with two additional Asp residues at each terminus was prepared. The resulting compound 6 is
soluble in excess of 200 M. Prior work on the binding of Q8•MV to tryptophan derivatives and Trpcontaining peptides suggests that the negative charges will have negligible effect on binding. 3) All
structures must be designed to minimize unintended adhesion of Q8 to sufficiently hydrophobic and/or
electropositive sites. We addressed this concern by placing positive charges on only the viologen
groups and by keeping alkyl chains to a length of three or fewer carbons.18 N-termini were acetylated,
and C-termini were primary amides in order to reduce the effects of electrostatic charge at these
positions.11

Self-Assembly of Receptors. All scaffolds, 1-3, bound to Q8 with Ka values of 2 x 106 M-1 per
binding site.15 The similarity of these binding constants to each other and to those observed previously
for the binding of Q8 to methyl viologen (Ka = 8.5 x 105 M-1) supports a similar mode of binding among
these complexes, demonstrates that linking viologen groups to these scaffolds does not diminish their
ability to bind to Q8, and exemplifies the non-cooperativity of this process. The small increase in the
binding affinity to Q8 for scaffolds 1-3 relative to methyl viologen may be due to additional dipoledipole interactions between Q8 and the amide NH groups on the linker and/or scaffold, as observed in
previous structural studies of Q8•peptide complexes.19 The ability of scaffolds 2 and 3 to bind two and
three equivalents of Q8, respectively, with no change in binding affinity shows that the multivalent
scaffolds are able to accommodate the steric demands of multiple Q8 molecules without an energetic
penalty.

Monovalent Peptide Targets. Receptor complexes, 1•Q8, 2•Q82, and 3•Q83, bound to monovalent
10

target peptides, 4, with Ka values of approximately 2 x 104 M-1 per binding site.15 The consistency
among these values and that observed previously for Q8•MV binding to Gly-Gly-Trp-Gly-Gly (Ka = 2.5
x 104 M-1)11 supports a similar mode of binding among these complexes, shows that linkage of
viologen•Q8 complexes to these scaffolds does not adversely affect their ability to bind to Trpcontaining peptides, and exemplifies the noncooperativity of this process. Moreover, the binding of
multivalent receptor complexes, 2•Q82 and 3•Q83, to two and three equivalents, respectively, of
monovalent peptide shows that the multivalent receptors are able to simultaneously accommodate the
steric demands of multiple monovalent target molecules with no energetic penalty. The consistency and
predictability observed for the binding of Q8 and, subsequently, of monovalent peptide establishes an
essential baseline for their comparison to multivalent analogues.

Divalent Peptide Targets: Mode of Binding. In studying the binding of divalent receptors, 2•Q82,
to their analogous multivalent target peptides, 5, we first needed to provide evidence for the mode of
binding. Specifically, we were concerned about the formation of supramolecular oligomers instead of,
or in addition to, the desired discrete multivalent complexes (Figure 5). To assign the mode of binding,
we present the following case.
Our system has the characteristic that simultaneous inclusion of viologen and indole groups in the
cavity of Q8 produces a quantitative increase in visible absorbance, which is due to the formation of a
charge-transfer complex between the two aromatic groups.11, 12b Therefore, the molar absorptivity due
to this charge-transfer complex is related directly to the number of simultaneous binding events per
molecule. The UV-visible spectral data (Figure 4) show that the charge-transfer absorptivities of the
divalent and trivalent complexes are two-fold and three-fold greater, respectively, than those of the
monovalent complexes.

This result shows that >95% of the possible Q8•viologen•tryptophan

complexes are simultaneously formed, and would be true only for discrete multivalent complexes as
well as for long (>20-mer) supramolecular oligomers.
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Figure 5. Schematic illustration of the stepwise binding of a divalent receptor with a divalent target peptide. In the first step, intermolecular
association (Kinter) yields a complex which can either close intramolecularly (Kintra) into a discrete complex or associate intermolecularly with
additional divalent compounds (Kintern) into a supramolecular oligomer.

ITC data for the formation of divalent (2•Q82•5) complexes show a single-phase isotherm (Figure
6), which fits well to a one-set-of-sites binding model and which has an inflection point at a 1:1 molar
ratio of target:receptor. Considering the argument presented in the following paragraph, this result
suggests that only one type of binding mode is occurring throughout the titration: 1) each molecule of
target peptide binds once to a receptor molecule; or 2) each molecule of target binds multiple times to a
receptor molecule. The UV-visible spectra discussed in the previous paragraph effectively rule out
option 1. Moreover, the observed binding enthalpies for the formation of 2•Q82•5 complexes are
approximately two-fold greater than those for the formation of 1•Q8•4, as expected for the binding of
two identical sites connected by a flexible linker.1a The combination of these results and the fact that
oligomeric species were not observed by mass spectrometry leads us to conclude that these complexes
form in a discrete, multivalent fashion.
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Figure 6. ITC data for the binding of divalent target peptide 5a to divalent receptor assembly 2a•Q82 at 27 °C in 10 mM sodium phosphate
buffer, pH 7.0. 5a was titrated at 0.60 mM into a 0.065 mM sample of 2a•Q82. The top plot shows the raw data for power applied as a
function of time. The integrated enthalpy values are plotted at the bottom as a function of the molar ratio of 5a:2a•Q82.

Supramolecular oligomerization can be ruled out on the basis of the ITC data by considering the
following argument. Early in the titration of a divalent target peptide into a solution of divalent
receptor, there is a vast excess of available receptor. If oligomerization were favored, then each
molecule of target would bind to two equivalents of receptor such that both tryptophan residues were
occupied. The Caruthers equation (Eq. 1) predicts the number average degree of polymerization, Xn, on
Xn, = 1/(1-p)

Eq. 1

the basis of extent of reaction, p. We determined p values from the equilibrium constants reported in
Table 2 and the experimental concentrations. This equation predicts an average length of two units at a
target:receptor ratio of 1:2, three units at a ratio of 3:4, and six units at the equivalence point. Over this
portion of the titration, newly titrated target molecules could bind to two free receptors or could link a
free receptor to a growing oligomer; in both cases, the measured enthalpy would reflect the binding of
both Trp residues per molecule of titrant. Near and after the equivalence point, however, the probability
13

of newly titrated target molecules to bind to multiple free receptor sites becomes very low. Therefore,
the titration experiment should show at least two phases: 1) before the equivalence point, a phase which
reflects the enthalpy of binding for two Trp residues per titrated target molecule; and 2) after the
equivalence point, a phase which reflects the enthalpy of binding of one Trp residue per titrated target
molecule. Our observation of a single-phase isotherm is inconsistent with this model, and thus we rule
out the formation of oligomers.

Divalent Peptide Targets: Effects of the Distance Between Binding Sites. In order to assess
whether the distance between binding sites influences the formation of divalent complexes, we varied
the oligo(Gly) linker between viologen groups in divalent scaffolds, 2, and between tryptophan residues
in divalent targets, 5, between four (2a and 5a) and six (2b and 5b) Gly units. As seen from the data in
Table 2, no significant difference was observed. Similarly there was no significant difference observed
for the analogous monovalent derivatives, 1a, 1b, 4a, and 4b. These results are not surprising given the
expectation that oligo(Gly) linkers would have little conformational preference.
The similarities observed here allow us to simplify subsequent analysis of the thermodynamic data
by averaging the values all four combinations of scaffold and target for each type of complex (Table 3).
For example, data for the formation of 1a•Q8•4a, 1b•Q8•4a, 1b•Q8•4a, and 1b•Q8•4b is shown simply
as 1•Q8•4, with an uncertainty determined by propagating the error in each experiment through the
calculation of an average.

Table 3. Average thermodynamic constants for Gly4 vs. Gly6 linkers.a

Receptor

Ka

G

H

-TS

(M-1)

(kcal/mol)

(kcal/mol)

(kcal/mol)

14

1•Q8•4

2.1 (±0.1) x 104

-6.0 (±0.1) -10.9 (±0.1)

4.9 (±0.1)

2•Q82•42

1.6 (±0.1) x 104

-5.8 (±0.1) -12.5 (±0.3)

6.7 (±0.3)

2•Q82•5

5.0 (±0.2) x 105

-7.8 (±0.1) -24.2 (±0.3)

16.4 (±0.4)

a

All values are averages of the constants reported in Table 2 for all four combinations of Gly4 and
Gly6 linkages. Errors were calculated by propagating the uncertainties reported in Table 2 through the
calculation of an average.

Divalent Peptide Targets: Thermodynamic Considerations. Table 3 allows us to conveniently
compare binding data for monovalent and divalent complexes. We observe an increase in K a of 31-fold
due to the second binding event. This increase is a significant improvement over monovalent binding,
but an ideal system could theoretically yield an increase on the order of 104-fold.1a The observed trend
in Ka values results from an approximate doubling of the binding enthalpies but at a substantial cost in
entropy. The additive enthalpy suggests that (i) both Trp residues are able to simultaneously associate
with their binding sites without steric penalty, and (ii) entropy is entirely to blame for the negative
cooperativity observed here.
In order to properly analyze the effects of divalent versus monovalent binding, we include a
treatment of symmetry factors, as outlined by Ercolani,3f and dissect this process into the constituent
inter- and intramolecular binding events. In the formation of the 2+2 complex, 2•Q82•5, binding of the
first Trp residue is designated as Kinter, and binding of the second as Kintra (Figure 5). A Kinter value of
5.5 x 103 M–1 is derived from the observed equilibrium constant (Kobs(1+1), Eq. 2)20 for the formation of
the
Kobs(1+1) = 4 Kinter

Eq. 2

monovalent complex, 1•Q8•4. The observed equilibrium constant for the formation of 2•Q82•5, Kobs(2+2)
(Eq. 3), is expressed in terms of Kinter and Kintra, where  = 2 for the overall reaction. This analysis
Kobs(2+2) = 2 Kinter Kintra

Eq. 3

yields a Kintra value of 45. Prior work4b, 21 has shown that flexible divalent compounds have an effective
molarity (EM) of approximately 5 mM, referring to the ratio of Kintra /2 Kinter (where  = 1/2). If our
15

Kinter = 5.5 x 103 M-1, then an EM of 5 mM would predict a Kintra value of 55. The similarity of this
prediction to the actual value reported here (45) provides another example of the regular behavior of this
system and thus its suitability as a model for multivalent interactions.
The detailed thermodynamic data provide an opportunity to dissect the formation divalent
complexes by isolating the effects of linking two monovalent receptors (1•Q8 vs. 2•Q82) or two
monovalent target peptides (4 vs. 5). The most direct comparison of thermodynamic data in these three
complexes would require normalization to the same number of Q8•viologen•Trp interactions per
complex. The modular design used in this system allows us to accomplish this estimation by doubling
the values of G, H, and -TS for the formation of 1•Q8•4 and 2•Q82•42 because these are average
values for each Q8•viologen•Trp interaction.22 From this comparison (Table 4), one can deduce that
linking two monovalent receptors (i.e., 2•Q82•42 vs. 1•Q8•4) results in a 3.2 kcal/mol increase in
exothermicity with an almost exact 3.6 kcal/mol compensation in entropic energy.

Linking two

monovalent target peptides (i.e., 2•Q82•5 vs. 2•Q82•42) results in a 3.0 kcal/mol entropic penalty with a
relatively small 0.8 kcal/mol loss in enthalpy. On the basis of this analysis, the suboptimal binding
affinity observed in the formation of the 2•Q82•5 complex derives primarily from an entropic penalty
associated with the binding of divalent versus monovalent peptide. This analysis is consistent with a
model in which significant conformational freedom is lost upon formation of the divalent complex.

Table 4. Dissection of the influence of linkage on divalent binding.a
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Complex

multiplier

G

H

-TS

(kcal/mol)

(kcal/mol)

(kcal/mol)

1•Q8•4

2

-12.0

-21.8

9.8

2•Q82•42

2

-11.6

-25.0

13.4

2•Q82•5

1

-7.8

-24.2

16.4

a

These are values from Table 3 multiplied by the “multiplier” in the second column so that all values
represent the binding of two Trp residues per complex.

Divalent Peptide Targets: A Model for Multivalent Binding. It is useful to compare our divalent
system to an antibody molecule (e.g., IgG), in which the binding of the second site confers a modest
100-fold increase in affinity.23 The wide range of conformations observed for IgG molecules suggests a
substantial conformational flexibility in the “hinge” that connects the two binding sites.24 The functional
role of this flexibility remains a topic of current research, but the enormous size and structural
complexity of antibody molecules substantially complicates these efforts. This example underscores the
challenges involved in carrying out detailed studies of multivalent processes on proteins. As in many
other successful areas of science, a good model system—one that embodies the essential characteristics
of multivalency but is especially easy to study—is needed.
In addition to its importance as a submicromolar receptor for peptides in aqueous solution, the
divalent system presented here has numerous features that make it well suited to serve as a model for
studying multivalent complexation: 1) The monovalent complex is well understood. 2) The mode of
divalent binding is simple, well defined, and similar to that observed for covalently linked multivalent
receptors. That is, assembly of the divalent complexes proceeds noncooperatively, divalent complexes
form in a discrete (non-oligomeric) fashion, and the observed intramolecular binding constant, Kintra, is
similar to that of other flexible divalent complexes. 3) Synthesis is straightforward. Solid-phase
synthetic methodology combined with noncovalent self-assembly enables the efficient synthesis of
receptors and iterative modification of their linkers. 4) Analysis is straightforward. ITC combined with
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UV-visible spectroscopy allows for rapid determination of binding mode and quantitative measurement
of the valency of the complex. Optical sensing of peptide targets is an additional benefit. 5) The system
has several features that are representative of multivalent complexes in biological systems.

The

complexes form in neutral, buffered aqueous solution, the target compounds are peptides, and there is an
observable increase in affinity due to multivalency. 6) The weaker than optimal increase in affinity is
representative of antibodies and is desirable because it provides ample opportunity to uncover design
principles for increasing the binding affinity through structure-activity studies.

Trivalent Peptide Target. Given the well-defined and predictable nature of the divalent complexes
described above, we asked what would happen if the valency were extended to three. Based on the lack
of distance-dependence observed in the divalent system, scaffold compound 3 and target peptide 6 were
designed with only four intervening Gly residues between binding sites. The charge-transfer
absorptivity of the trivalent complex, 3•Q83•6, is three times that observed for the monovalent
complexes, 1•Q8•4 (Figure 4). As discussed in detail for the divalent system above, this result
demonstrates that essentially all of the available tryptophan residues are bound simultaneously, but it
does not in itself allow for the unambiguous determination of binding mode. In the divalent complex,
the two binding sites per molecule allow for only two possible binding modes: discrete macocycles and
daisy-chain-like oligomers. In the trivalent system, the three binding sites per molecule enable more
possible configurations, but the observed condition that all sites are bound simultaneously suggests that
the only probable binding modes are discrete complexes and linear oligomers.
The ITC data for the trivalent complex shows a single transition centered at a 1:1 (6 : 3•Q83)
ratio (see Supporting Information, Figure S21).

In contrast to the divalent system, however, the

isotherm for the trivalent complex shows some asymmetry, with a steeper decrease in the magnitude of
enthalpy in the first 2/3 of the injections.16 This region fits well to a one-set-of-sites model, but the
more shallow curvature of the remaining 1/3 of the data points suggests an additional binding mode, the
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nature of which is unclear at this time. This result is not dramatic, but it is real, and it precludes the
definitive assignment of this complex as discrete versus oligomeric. Given that (i) there is a clear
midpoint at a 1:1 ratio, (ii) the first ~2/3 of the data points, including the early baseline and most of the
transition region, is well defined by the data, and (iii) the end of the titration is defined by the heat of
dilution, we estimated thermodynamic constants by fitting the first 2/3 of the titration data to a one-setof-sites model. It should be noted that the UV-visible spectroscopy data in Figure 4 were acquired at
the equivalence point, and thus are within the region defined by this analysis. Mass spectral data also
verify the presence of the 3•Q83•6 complex.
Although the binding mode is not definitive, the data provide a look at the properties of what is
likely a discrete trivalent complex. With these qualifications in mind, we observe an increase in K a of
~280-fold due to multivalency, which is an enhancement of ~10-fold for the addition of a third binding
site. This increase results from an approximate tripling of the favorable binding enthalpy and a more
than tripling of the unfavorable binding entropy. The additive enthalpy is very similar to that observed
for the divalent complexes; this similarity supports an assignment of a discrete trivalent complex.
As described above for the divalent complex, the observed binding constant for the formation of
3•Q83•6, Kobs(3+3), can be evaluated on the basis of the constituent inter- and intramolecular binding
constants, Kinter and Kintra. Using the approach detailed above for the divalent complexes,3f we derive a
Kinter value of 1.1 x 104 M–1 and a Kintra value of 15. The Kintra value is therefore approximately 3-fold
smaller than that of the divalent complex. Based on the argument that only K values of the same
dimensionality can be directly compared to assess cooperativity,3f we conclude that the trivalent system
shows a small degree of negative cooperativity as compared to the divalent complex.
Also as described for the divalent complex, the thermodynamic data for 3•Q83•6 can be dissected to
assess the relative effects of linking three monovalent scaffolds (i.e., 1•Q8•4 vs. 3•Q83•43) or three
monovalent targets (i.e., 3•Q83•43 vs. 3•Q83•6). In order to normalize to the same number of binding
events per complex, however, the thermodynamic state functions for 1•Q8•4 and 3•Q83•43 must be
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multiplied by a factor of 3. The resulting values (Table 5) show that linkage of three monovalent
scaffolds leads to a 3.9 kcal/mol increase in favorable enthalpy with a compensating 4.5 kcal/mol
increase in unfavorable entropy. Linkage of three monovalent target peptides provides an additional 2.8
kcal/mol in favorable enthalpy but with a massive 11 kcal/mol loss in entropic energy. This trend is
very similar to that observed for the divalent complex (as in Table 5); this similarity further supports an
assignment of a discrete trivalent complex. The increasing loss in entropy in this system versus the
divalent complexes is likely due to a decreasing probability of adopting a conformation in which all
three sites are simultaneously bound without enthalpic penalty due to steric strain. If this trend is
linearly extrapolated to complexes of higher valency, we would predict that starting with a heptavalent
complex, the influence of multivalency would actually reduce the overall binding affinity.
Multivalent binding is often thought to be an entropically favorable process due to the reduced
entropic penalty of translational and rotational freedom upon binding of two n-valent compounds as
compared to the binding of n pairs monovalent analogues.1a The contribution of this entropic advantage
to the free energy of binding has been approximated at ~5 kcal/mol per increase in the reaction
order.3a,25 Using this approximation, the entropic contribution to the free energy of binding of a divalent
complex should be twice that of a monovalent complex less 5 kcal/mol; we observe an additional 8-12
kcal/mol entropic penalty beyond this approximation. Similarly, the entropic contribution to the free
energy of binding of a trivalent complex should be three times that of a monovalent complex less 10
kcal/mol; we observe an additional 21-26 kcal/mol entropic penalty beyond this approximation. These
results are in stark contrast to the expected entropic advantage of multivalency. The nature of this effect
remains unclear.
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Table 5. Dissection of the influence of linkage on trivalent binding.a

Complex

multiplier

G

H

-TS

(kcal/mol)

(kcal/mol)

(kcal/mol)

1•Q8•4

3

-18.0

-32.7

14.7

3•Q83•43

3

-17.4

-36.6

19.2

3•Q83•6

1

-9.2

-39.4

30.2

a

These are values from Tables 2 (1•Q8•4) and 3 (3•Q83•43 and 3•Q83•6) multiplied by the
“multiplier” in the second column so that all values represent the binding of three Trp residues per
complex.

Conclusion
This paper demonstrates a novel biomimetic approach to the construction of well-defined
multivalent receptors via molecular self-assembly. We present a new class of synthetic receptors that
assemble spontaneously from a modular scaffold presenting 1-3 viologen groups and an equivalent
number of Q8 molecules. This noncovalent synthetic approach provides unparalleled economy for the
purpose of iterative design and synthesis of multivalent receptors.

We show that preassembled

receptors bind to peptides containing multiple Trp residues in a multivalent fashion with affinity gains
of 31-280-fold due to multivalency. The built-in optical sensor for tryptophan enables rapid and direct
determination of the extent of valency using UV-visible spectroscopy, thus overcoming a common
pitfall in the analysis of multivalent complexes. This technique, in combination with calorimetry and
careful modular design of the scaffolds and targets, allows for convenient determination of the binding
mode and comprehensive analysis of the binding thermodynamics. In addition to these advantages in
synthesis and analysis, this system has several characteristics that make it remarkably well suited as a
model for multivalent complexes:

1) It works in water.

2) The monovalent complex is well
21

characterized. 3) Receptor assembly is noncooperative, and binding is additive; these features hugely
simplify the equilibrium analysis. This system should facilitate iterative studies of structure-activity
relationships in multivalent complexes, such as the effects of conformational entropy, ligand geometry,
and higher valency. These studies are currently underway and will be reported in due course.
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